CXCR4-guided liposomes regulating hypoxic and immunosuppressive microenvironment for sorafenib-resistant tumor treatment
Clinical sorafenib treatment could activate C-X-C receptor type 4 (CXCR4)/stromal source factor-1α (SDF-1α) axis to aggravate intra-tumoral hypoxia of hepatocellular carcinoma (HCC), which further leads to progression, invasion, metastasis, and immunosuppression of tumors and in return causes resist...
Main Authors: | Yuehua Wang, Zhenjie Wang, Fei Jia, Qing Xu, Zhilin Shu, Junlin Deng, Aimin Li, Meng Yu, Zhiqiang Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
KeAi Communications Co., Ltd.
2022-11-01
|
Series: | Bioactive Materials |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2452199X22000032 |
Similar Items
-
Tanshinone IIA promotes vascular normalization and boosts Sorafenib’s anti-hepatoma activity via modulating the PI3K-AKT pathway
by: Chengdong Qin, et al.
Published: (2023-06-01) -
2-Methoxyestradiol loaded mesoporous polydopamine nanoprobes for hypoxia alleviation and sorafenib synergistic treatment of hepatocellular carcinoma
by: Peifeng Wang, et al.
Published: (2023-08-01) -
The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma
by: Siqi Chen, et al.
Published: (2023-07-01) -
Mechanism of sorafenib resistance associated with ferroptosis in HCC
by: Lingling Guo, et al.
Published: (2023-06-01) -
Dose-Dependent Sorafenib-Induced Immunosuppression Is Associated with Aberrant NFAT Activation and Expression of PD-1 in T Cells
by: Renuka V. Iyer, et al.
Published: (2019-05-01)